Sheng Ding News Today

OpenAI CEO Sam Altman has invested a whopping $180 million in a startup that's looking for novel ways to extend human longevity. As Bloomberg, which recently got an insider look at the company, reports, the company called Retro Biosciences has an unusual way of conducting its research, and is investigating not just one area of […]

News and Press Release in English on World and 1 other country about Contributions and Health; published on 15 Jun 2023 by Gates Foundation

Microsoft founder Bill Gates arrived in Beijing, lavishly praised China, and visited with his "old friend," dictator Xi Jinping.

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have been given a consensus rating of “Hold” by the twenty-three research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have issued a buy recommendation on the […]

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Stifel Nicolaus from $5.30 to $5.00 in a research report sent to investors on Thursday, The Fly reports. Several other analysts also recently weighed in on the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating […]

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its target price lowered by Cantor Fitzgerald from $8.00 to $5.00 in a report published on Thursday, The Fly reports. FATE has been the topic of a number of other reports. Morgan Stanley reduced their price objective on shares of Fate Therapeutics from $35.00 to $8.00 and set […]

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price objective cut by Stifel Nicolaus from $5.30 to $5.00 in a report issued on Thursday morning, The Fly reports. Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating and reduced their […]

Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […]

Surrozen (NASDAQ:SRZN – Get Rating) and Fate Therapeutics (NASDAQ:FATE – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Profitability This table compares Surrozen and Fate Therapeutics’ net margins, […]

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at SVB Leerink issued their Q4 2024 earnings per share estimates for Fate Therapeutics in a research report issued on Thursday, May 4th. SVB Leerink analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter. SVB Leerink […]